Indigenous Stents :-
New Technologies & Clinical Data

Dr. A. Sreenivas Kumar

M.D., D.M., FACC (USA)

Chief Cardiologist, The Heart Centre

Continental Institute of CardioVascular Sciences

Gachibowli, Hyderabad, AP, INDIA

Disclosure Statement of Financial Interest

I, Dr.A.Sreenivas Kumar -DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

M' Sure - Cr

Chromium Cobalt Coronary Stent



- M'Sure–Cr is made up of Cobalt Chromium L605 which contains no Molybdenum and only 10% of Nickel compared to other brands which uses Cobalt Alloy MP35N, which has 35% Nickel and 10% of Molybdenum.

Multimedics
Devices for Life...

M' Sure - S
Sirolimus Eluting CoCr stent system



Optimal balance of High radial strength of 1.1 bar and ultra low strut thickens of 59µm.
MSure –S uses a validated formulation of low dose Sirolimus (1.30µg/mm2) timed to elute in 30days from a biodegradable and biocompatible polymer base, which degrades simultaneously



PRISM - Basket of Clinical Trials

PRISM - Basket of Clinical Trials

- **A Prospective Registry** to **Investigate Safety and Efficacy of M'Sure-S (Sirolimus Eluting Coronary Stent)**
- PRISM trials are series of studies funded by Multimedics in order to investigate and suitably demonstrate the safety and efficacy of M'Sure-S (Sirolimus eluting coronary stent system) in a broad spectrum of clinical indications to build confidence across the globe with operators in different patients with different clinical history that react differently to the same treatment.

PRISM - PILOT

- **A Prospective Registry** to **Investigate Safety and Efficacy of M'Sure-S (Sirolimus Eluting Coronary Stent)**
- Results: No MACE was observed, the median in-stent late luminal loss in subjects studied by QCA was 0.05 mm, with 0% binary restenosis at six month angiographic follow-up. No stent thrombosis was observed up to six month follow up.

PRISM - Indian sub continent

- **A Prospective Registry** to **Investigate Safety and Efficacy of M'Sure-S (Sirolimus Eluting Coronary Stent)**
- The primary safety and efficacy end-points are major adverse cardiac events (MACE) at 30 days and in-stent late lumen loss at 9 months, measured using QCA. Secondary safety and efficacy end-points included angiographic binary restenosis at 9 month angiographic follow-up. Other end-points included the occurrence of stent thrombosis (acute, subacute, late and very late), percentage of diameter stenosis measured by QCA.

PRISM - Basket of Clinical Trials

PRISM - Global

- **A Prospective Registry** to **Investigate Safety and Efficacy of M'Sure-S (Sirolimus Eluting Coronary Stent)**
- We have selected few centres across the globe, selection process and enrolment is going on.

- The primary safety and efficacy end-points are major adverse cardiac events (MACE) at 30 days and in-stent late lumen loss at 9 months, measured using QCA. Secondary safety and efficacy end-points included angiographic binary restenosis at 9 month angiographic follow-up. Other end-points included the occurrence of stent thrombosis (acute, subacute, late and very late), percentage of diameter stenosis measured by QCA.

PRISM - M

- **A Prospective Registry** to **Investigate Safety and Efficacy of My Stent - S (Sirolimus Eluting Coronary Stent)**
- Results: No MACE was observed, the median in-stent late luminal loss in subjects studied by QCA was 0.05 mm, with 0% binary restenosis at six month angiographic follow-up. No stent thrombosis was observed up to six month follow up.